Multivariable models evaluating MRD– CR, OS, and EFS for CLAG-M/sorafenib RP2D vs historical CLAG-M cohort
| Covariate . | OR for MRD– CR . | 95% CI . | P value . | HR for OS . | 95% CI . | P value . | HR for EFS . | 95% CI . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| CLAG-M/Sorafenib (ref = CLAG-M) | 1.95 | 0.57-6.63 | .28 | 0.24 | 0.07-0.82 | .023 | 0.16 | 0.05-0.53 | .003 |
| Age | 0.94 | 0.89-1.00 | .05 | 1.04 | 1.00-1.09 | .05 | 1.05 | 1.01-1.09 | .02 |
| Secondary disease∗ | 0.68 | 0.18-2.63 | .58 | 2.52 | 01.02-6.23 | .04 | 1.34 | 0.58-3.12 | .49 |
| FLT3-mutated | 2.21 | 0.40-12.15 | .36 | 0.85 | 0.27-2.66 | .77 | 0.69 | 0.23-2.04 | .50 |
| Intermediate risk† | 0.18 | 0.03-1.01 | .05 | 3.46 | 1.12-10.65 | .03 | 3.15 | 1.18-8.37 | .02 |
| Adverse risk† | 0.14 | 0.03-0.74 | .02 | 3.02 | 1.01-9.02 | .05 | 2.50 | 1.00-6.22 | .05 |
| Two induction cycles (ref = 1 induction cycle) | —‡ | 0.77 | 0.22-2.68 | .69 | 1.36 | 0.51-3.63 | .54 |
| Covariate . | OR for MRD– CR . | 95% CI . | P value . | HR for OS . | 95% CI . | P value . | HR for EFS . | 95% CI . | P value . |
|---|---|---|---|---|---|---|---|---|---|
| CLAG-M/Sorafenib (ref = CLAG-M) | 1.95 | 0.57-6.63 | .28 | 0.24 | 0.07-0.82 | .023 | 0.16 | 0.05-0.53 | .003 |
| Age | 0.94 | 0.89-1.00 | .05 | 1.04 | 1.00-1.09 | .05 | 1.05 | 1.01-1.09 | .02 |
| Secondary disease∗ | 0.68 | 0.18-2.63 | .58 | 2.52 | 01.02-6.23 | .04 | 1.34 | 0.58-3.12 | .49 |
| FLT3-mutated | 2.21 | 0.40-12.15 | .36 | 0.85 | 0.27-2.66 | .77 | 0.69 | 0.23-2.04 | .50 |
| Intermediate risk† | 0.18 | 0.03-1.01 | .05 | 3.46 | 1.12-10.65 | .03 | 3.15 | 1.18-8.37 | .02 |
| Adverse risk† | 0.14 | 0.03-0.74 | .02 | 3.02 | 1.01-9.02 | .05 | 2.50 | 1.00-6.22 | .05 |
| Two induction cycles (ref = 1 induction cycle) | —‡ | 0.77 | 0.22-2.68 | .69 | 1.36 | 0.51-3.63 | .54 |
Defined as AML transformed from antecedent hematologic disorder or AML/myelodysplastic syndrome in a patient who had previously received cytotoxic therapy.
Based on ELN 2017 cytogenetic/molecular criteria.
The number of induction cycles is not included in multivariable model because of model instability resulting from small sample sizes in subgroups.